Vedolizumab: An α4β7 Integrin Inhibitor for Inflammatory Bowel Diseases

Annals of Pharmacotherapy

Volumn 48, Issue 12, 2014, Pages 1629-1635

  Smith, Michael A ^a   Mohammad, Rima A ^b  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Crohn s disease; ulcerative colitis; vedolizumab

Indexed keywords

CHOLERA VACCINE; CORTICOSTEROID; HEPATITIS B VACCINE; NATALIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VEDOLIZUMAB; INTEGRIN; INTEGRIN ALPHA4BETA7; MONOCLONAL ANTIBODY;

ARTHRALGIA; COUGHING; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DRUG APPROVAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; HUMAN; INFLAMMATORY BOWEL DISEASE; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; REVIEW; RHINOPHARYNGITIS; TREATMENT RESPONSE; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; COLITIS, ULCERATIVE; INFLAMMATORY BOWEL DISEASES; MALE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTEGRINS; MALE;

EID: 84921490479     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014549799     Document Type: Review

References (16)

1. Kornbluth A,Sachar DB.Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.Am J Gastroenterol. 2010;105:501-523
2. Lichtenstein GR,Hanauer SB,Sandborn WJ.Management of Crohn’s disease in adults.Am J Gastroenterol. 2009;104:465-483
3. Colombel JF,Sandborn WJ,Reinisch W, et al.Infliximab, azathioprine, or combination therapy for Crohn’s disease.N Engl J Med. 2010;362:1383-1395
4. Peake ST,Bernardo D,Mann ER,Al-Hassi HO,Knight SC,Hart AL.Mechanisms of action of anti-tumor necrosis factor alpha agents in Crohn’s disease.Inflamm Bowel Dis. 2013;19:1546-1555
5. Goodman SL,Picard M.Integrins as therapeutic targets: trends in pharmacological sciences.Trends Pharmacol Sci. 2012;33:405-412
6. Bloomgren G,Richman S,Hotermans C, et al.Risk of natalizumab-associated progressive multifocal leukoence-phalopathy.N Engl J Med. 2012;366:1870-1880
7. Deerfield, IL: Takeda Pharmaceuticals; 2014:
8. Soler D,Chapman T,Yang LL,Wyant T,Egan R,Fedyk ER.The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.J Pharmacol Exp Ther. 2009;330:864-875
9. Parikh A,Leach T,Wyant T, et al.Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study.Inflamm Bowel Dis. 2012;18:1470-1479
10. Feagan BG,Rutgeerts P,Sands BE, et al.Vedolizumab as induction and maintenance therapy for ulcerative colitis.N Engl J Med. 2013;369:699-710
11. Sandborn WJ,Feagan BG,Rutgeerts P, et al.Vedolizumab as induction and maintenance therapy for Crohn’s disease.N Engl J Med. 2013;369:711-721
12. Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration. In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. 2014. Available from: (http://clinicaltrial.gov/ct2/show/NCT02163421?term=vedolizumab&rank=2): NCT02163421. Accessed August 8, 2014.
13. Milch C,Wyant T,Xu J, et al.Vedolizumab, a monoclonal antibody to the gut homing alpha4beta7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype.J Neuroimmunol. 2013;264:123-126
14. Sands BE,Feagan BG,Rutgeerts P, et al.Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment had failed.Gastroenterology.:
15. Wyant T,Leach T,Sankoh S, et al.Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results.Gut. 2014;:
16. Parikh A,Fox I,Leach T, et al.Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease.Inflamm Bowel Dis. 2013;19:1691-1699